Effectiveness of Cidofovir in Treating Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML) by Mansoor, Salman
Pakistan Journal of Neurological 
Sciences (PJNS) 
Volume 16 Issue 1 Article 11 
3-2021 
Effectiveness of Cidofovir in Treating Natalizumab-Associated 
Progressive Multifocal Leukoencephalopathy (PML) 
Salman Mansoor 
University of Calgary, Alberta, Canada 
Follow this and additional works at: https://ecommons.aku.edu/pjns 
 Part of the Neurology Commons 
Recommended Citation 
Mansoor, Salman (2021) "Effectiveness of Cidofovir in Treating Natalizumab-Associated Progressive 
Multifocal Leukoencephalopathy (PML)," Pakistan Journal of Neurological Sciences (PJNS): Vol. 16 : Iss. 
1 , Article 11. 
Available at: https://ecommons.aku.edu/pjns/vol16/iss1/11 




Is Cidofovir treatment in Natalizumab-associated Progressive Multifocal Leukoencephalopathy effective in MS 
Patients? 
Background:
Natalizumab (Nz) a monoclonal antibody has been in medicinal use for treatment of Relapsing Remitting Multiple 
Sclerosis (RRMS) since 2004. Progressive Multifocal Leukoencephalopathy (PML) is one of its serious risks which is a 
demyelinating disorder of brain associated with John Cunningham Virus (JCV). There have been 801 cases up till 
December 2018 which were reported with its use1.  Lack of prospective trials and retrospective studies due to small 
number of these cases there is no consensus on Nz-associated PML treatment. To date there is no cure for this 
condition and there is a debate on effectiveness of different modalities2. Cidofovir an antiviral drug which is used in 
cytomegalovirus retinitis, Aciclovir-resistant HSV infections3, 4. The antiviral properties of Cidofovir are attributed to its 
active metabolite Cidofovir diphosphate which inhibits viral replication by impeding viral DNA ploymerases 5. Cidofovir 
is effective in polyomavirus like BK-virus in kidney transplant recipients. JCV belongs to the same family of 
Polyomaviruses5. Cidofovir has been used in selected cases with PML in various immunosuppressed states, 
hematological malignancies, post-transplant and HIV for the treatment of PML. This CAT aims to look at the evidence 





An online search including Pubmed and Cochrane library was conducted dated 12th April 2019 to look for available 




Search in Pubmed Central showed 71 studies and case reports with the search term 
There were 14 studies and case reports which were studied in depth for this CAT 4 case reports which fulfilled the 
criteria were included 10 studies which partially encompassed the scope of this CAT were discussed in the references. 
(Appendix 1)
Search in the Cochrane library with the search terms showed 3 reviews and 120 controlled trials These reviews and 
controlled trials were beyond the scope of this study, so these were excluded. (Appendix 2)
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Evidence Included in This CAT: 
1. Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. 
Himedan M, Camelo-Piragua S, Mills EA, Gupta A, Aburashed R, Mao-Draayer Y. J Investig Med High Impact Case Rep. 
2017 Sep 27;5(3):2324709617734248. doi: 10.1177/2324709617734248. eCollection 2017 Jul-Sep. (Case 
Report 1 in Table.1)
2. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. Langer-Gould A, Atlas SW, Green 
AJ, Bollen AW, Pelletier D. N Engl J Med. 2005 Jul 28;353(4):375-81. Epub 2005 Jun 9. (Case Report 3 in Table.1)
3. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Hervás JV, 
Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C. 
Neurodegener Dis Manag. 2015 Oct;5(5):399-402. doi: 10.2217/nmt.15.42. Epub 2015 Oct 30. (Case Report 4 in 
Table 1)
4. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons 
from 28 cases. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. The Lancet Neurology. 2010 
Apr;9(4):438-46.
Table 1. Cidofovir use in associated Progressive Multifocal Leukoencephalopathy in MS
Summary:
Natalizumab associated PML is one of the major side-effects in Multiple Sclerosis patients. The long-term outcomes 
vary in individual cases. Patients who develop the condition mainly have two strong associations, the JCV serology titer 
index and the duration of treatment. In search for answering the question if Cidofovir is effective treatment there is 
ancillary evidence from case reports supporting it in Natalizumab associated PML. Owing to the small number of these 
cases a randomized controlled trial encompassing different drugs and including outcome variables is not possible.
An interesting review on PML recommended conflicting evidence on effectiveness of Cidofovir in PML6. Studies and 
reports which suggested ineffectiveness of cidofovir were both conducted in AIDS-associated PML7-9. Three interesting 
non-AIDS related case reports supported Cidofovir with positive outcomes 10-12. The results of these outcomes in 
Natalizumab associated PML can they be generalized, remains ambiguous. 
In a case series of 28 Natalizumab associated patients 2 of the patients received Cidofovir their treatment outcomes 
at 3-months showed stabilization 13.  Adjunctive therapy including plasma exchange, and Cidofovir in one patient was 
used. The second patient was treated with Cidofovir, Mirtazepine, Mefloquine and Plasma Exchange13.
In this CAT an analysis of 5 cases were included of Natalizumab associated PML which were treated with Cidofovir in 
different treatment combinations. Owing to small number of cases which encompassed this CAT it is difficult to come 
to any specific conclusion. There was clinical stabilization in 4 cases that was achieved, and 1 case had an initial 
deterioration. In all the 5 cases there was a serological remission at the end. One strong reason for such an 
observation could be a publication bias. Multi-drug regimen specific to each case was used including Mirtazepine, 
Mefloquine, Cidofovir, Cytarabine, and plasma exchange. These are further individually classified in Table.1.
Clinical Bottom Line:
It’s very difficult to generalize the results of this CAT due to the small number of cases which are associated with 
Natalizumab treated with Cidofovir and an unavailability of Randomized controlled trials. 
However, the results which did encompass a small number of patients were suggestive of serological remission, and 
clinical stabilization with Cidofovir and the adjunctive therapy.
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